← All organizations
Highest phase reached
Phase 4
First clinical trial
Feb 1, 2007Last known activity
Oct 31, 2022
Acquired by Syneos Health on Oct 29, 2020
Timeline
1980s
- Jun 1, 1986
Synteract, Inc.— Founded
2010s
- Mar 4, 2013
Harrison Clinical Research— Acquired
- Jul 11, 2018
Cu-Tech— Acquired
2020s
- Oct 29, 2020
Syneos Health— Acquired By
Drugs by trial phase (43 distinct, 37 trials)
Phase 4 (1 own, 1 via acquisition)
Phase 3 (9 own, 2 via acquisition)
Phase 2 (11 own, 7 via acquisition)
Phase 1 (6 own, 2 via acquisition)
Other trials (2 own, 2 via acquisition)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Charcot-Marie-Tooth Disease
- Cystic Fibrosis
- Dental Caries
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Fibrosis
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Hereditary Sensory and Motor Neuropathy
- Hot Flashes
- Hypoglycemia
- Infections
- Lymphoma, Non-Hodgkin
- Mesothelioma
- Migraine Disorders
- Molluscum Contagiosum
- Nerve Compression Syndromes
- Ovarian Neoplasms
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Tooth Diseases
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (26)
- NCT05534620CollaboratorPhase 1Oct 31, 2022
- NCT04535531CollaboratorPhase 3Sep 1, 2020
- NCT04465916CollaboratorPhase 2May 12, 2020
- NCT04013334CollaboratorPhase 2Jul 31, 2019
- NCT03927703CollaboratorPhase 3Jun 30, 2019
- NCT03927716CollaboratorPhase 3Jun 3, 2019
- NCT03785366CollaboratorPhase 3Dec 17, 2018
- NCT03180307CollaboratorPhase 3Jan 26, 2018
- NCT03283462CollaboratorN/AJan 15, 2018
- NCT03216226CollaboratorPhase 3Jun 28, 2017
- NCT03023540CollaboratorPhase 3Mar 7, 2017
- NCT03931993CollaboratorPhase 1Jan 16, 2017
- NCT03014115CollaboratorN/ANov 30, 2016
- NCT02882191CollaboratorPhase 2Nov 1, 2016
- NCT02834312CollaboratorPhase 2May 1, 2016
Details
- Founded
- Carlsbad, CA, US Jun 1, 1986
- Last known activity
- Oct 31, 2022
Notes
CRO